EPS Calculation (Details) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
Numerator:
Net income	$ 76,188		$ 77,351
Dividends declared on preferred stock	(3,750)		(2,040)
Dividends, DERs and undistributed earnings allocated to participating securities	(278)		(321)
Net income to common stockholders - basic and diluted	$ 72,160		$ 74,990
Denominator:
Weighted average common shares for basic and diluted earnings per share	365,848,000	[1]	358,110,000	[1]
Basic and diluted EPS (in dollars per share)	$ 0.20		$ 0.21
Anti-dilutive securities excluded from diluted earnings per share calculations (in shares)	1,600,000
Stock options
Denominator:
Anti-dilutive securities excluded from diluted earnings per share calculations (in shares)	5,000
Weighted average exercise price (in dollars per share)	$ 8.40
Weighted average remaining contractual life	4 months 10 days
Restricted common stock
Denominator:
Anti-dilutive securities excluded from diluted earnings per share calculations (in shares)	415,000
Weighted average grant date fair value (in dollars per share)	$ 7.49
Restricted Stock Units
Denominator:
Anti-dilutive securities excluded from diluted earnings per share calculations (in shares)	1,200,000
Weighted average grant date fair value (in dollars per share)	$ 6.81

[1] At March 31, 2014, the Company had an aggregate of 1.6 million equity instruments outstanding that were not included in the calculation of diluted EPS for the three months ended March 31, 2014, as their inclusion would have been anti-dilutive. These equity instruments were comprised of 5,000 stock options with a weighted average exercise price of $8.40 and a weighted average remaining contractual life of 0.36 years, approximately 415,000 shares of restricted common stock with a weighted average grant date fair value of $7.49 and approximately 1.2 million RSUs with a weighted average grant date fair value of $6.81. These equity instruments may have a dilutive impact on future EPS.